Abstract:Purpose The primary objective of the study is to enhance the accuracy and efficiency of assessing the proliferation index in cancer cells, specifically focusing on the role of Ki-67. The purpose is to address the limitations of traditional visual assessments conducted by pathologists by integrating AI technologies, particularly deep learning. By accurately computing the percentage of Ki-67-labeled cells, the research aims to streamline the diagnostic process, reduce subjectivity and contribute to the advancement of diagnostic precision in pathological anatomy. Design/methodology/approach The research employs a methodological approach that integrates Ki-67, a non-histone nuclear protein, as a vital biomarker for assessing the proliferative status of cancer cells. Given the challenges associated with traditional visual assessments by pathologists, including inter- and intra-observer variability and time-consuming efforts, the study adopts a novel methodology leveraging artificial intelligence (AI) solutions. Deep learning is applied to precisely calculate the percentage of Ki-67-labeled cells. The process involves pathologists delineating the tumor area at x40 magnification, enabling the segmentation of various cell types (positive, negative and tumor-infiltrating lymphocytes). The subsequent percentage calculation enhances efficiency and minimizes subjectivity in the diagnostic process. Findings Despite inherent errors, the research findings indicate that the model surpasses existing benchmarks, showcasing superior accuracy in terms of average error measurement. The comparison with diverse datasets and benchmarking against pathologists' diagnoses contributes empirical evidence to support the effectiveness of the AI-based model in accurately computing the percentage of Ki-67-labeled cells. These findings signify a noteworthy advancement in diagnostic methodologies and reinforce the potential of AI technologies in improving the precision of cancer diagnostics within the realm of pathological anatomy. Originality/value The research contributes to the field by introducing an innovative approach that combines Ki-67 as a biomarker and AI technologies for improved diagnostic precision. The originality lies in the utilization of deep learning to calculate the percentage of labeled cells, mitigating the challenges associated with manual assessments. The validation of the model against diverse datasets and benchmarking against pathologists' diagnoses demonstrates its superior accuracy, highlighting the value of integrating AI in pathological anatomy for enhanced diagnostic outcomes. The study represents a significant stride in original research, offering novel insights and methodologies in the pursuit of more precise cancer diagnostics.

Improving Ki67 assessment concordance by the use of an artificial intelligence‐empowered microscope: a multi‐institutional ring study

AI improves accuracy, agreement and efficiency of pathologists for Ki67 assessments in breast cancer

Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study

AI-powered precision: breast carcinoma diagnosis through digital proliferation index (Ki-67) assessment in pathological anatomy

Comparison of FDA-Approved vs. Mayo Clinic’s Ki-67 Immunostaining Protocols for Breast Cancer Specimens: A Quantitative Analysis Using Artificial Intelligence (AI) Based Image Analysis Algorithms

Ki‐67 evaluation using deep‐learning model‐assisted digital image analysis in breast cancer

Reliability and Variability of Ki-67 Digital Image Analysis Methods for Clinical Diagnostics in Breast Cancer

An Interobserver Reproducibility Analysis of Ki67 Visual Assessment in Breast Cancer

Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

A deep learning model to predict Ki-67 positivity in oral squamous cell carcinoma

Automated Ki‐67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry

The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer

Microscope Based HER2 Scoring System

Peer-to-peer validation of Ki-67 scoring in a pathology quality circle as a tool to assess interobserver variability: are we better than we thought?

Determination of Ki-67 indices in neuroendocrine tumours of the gastrointestinal tract: the past, the present, and the future

Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration

An Interobserver Reproducibility Analysis of Size-Set Semiautomatic Counting for Ki67 Assessment in Breast Cancer

Artificial intelligence enhances whole‐slide interpretation of PD‐L1 CPS in triple‐negative breast cancer: A multi‐institutional ring study

Automated quantitative analysis of Ki-67 staining and HE images recognition and registration based on whole tissue sections in breast carcinoma

Fully Automated Artificial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer: A Multireader Study